-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis Shares Updated Eti-Cel Phase 1 Data At ASH 2025 In r/r NHL, With IL-2 Support Cohort Enrollment Starting Q1 2026

Benzinga·12/08/2025 07:42:04
Listen to the news
  • Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy
  • In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistence
  • IL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026